NASDAQ:TVGN Semper Paratus Acquisition (TVGN) Stock Price, News & Analysis $0.98 -0.03 (-2.97%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.00 (+0.31%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Semper Paratus Acquisition Stock (NASDAQ:TVGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TVGN alerts:Sign Up Key Stats Today's Range$0.97▼$1.0250-Day Range$0.87▼$1.4352-Week Range$0.26▼$3.09Volume680,884 shsAverage Volume1.45 million shsMarket Capitalization$180.21 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. Read More Semper Paratus Acquisition Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreTVGN MarketRank™: Semper Paratus Acquisition scored higher than 75% of companies evaluated by MarketBeat, and ranked 258th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSemper Paratus Acquisition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSemper Paratus Acquisition has only been the subject of 1 research reports in the past 90 days.Read more about Semper Paratus Acquisition's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.86% of the float of Semper Paratus Acquisition has been sold short.Short Interest Ratio / Days to CoverSemper Paratus Acquisition has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Semper Paratus Acquisition has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSemper Paratus Acquisition does not currently pay a dividend.Dividend GrowthSemper Paratus Acquisition does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.86% of the float of Semper Paratus Acquisition has been sold short.Short Interest Ratio / Days to CoverSemper Paratus Acquisition has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Semper Paratus Acquisition has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.23 News SentimentSemper Paratus Acquisition has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Semper Paratus Acquisition this week, compared to 4 articles on an average week.Search Interest5 people have searched for TVGN on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Semper Paratus Acquisition insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,768,993.00 in company stock.Percentage Held by Insiders73.24% of the stock of Semper Paratus Acquisition is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Semper Paratus Acquisition's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Semper Paratus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address TVGN Stock News HeadlinesTevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected3 hours ago | globenewswire.comRepeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on OncologyAugust 13 at 3:53 PM | globenewswire.comNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.August 14 at 2:00 AM | Brownstone Research (Ad)Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 BillionAugust 11 at 3:45 PM | globenewswire.comREPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 BillionAugust 11 at 1:24 PM | globenewswire.comTevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to FollowAugust 11 at 11:58 AM | globenewswire.comREPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to StockholdersAugust 11 at 9:28 AM | globenewswire.comREPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase PositionsAugust 8, 2025 | globenewswire.comSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Semper Paratus Acquisition's stock was trading at $1.03 at the beginning of 2025. Since then, TVGN stock has decreased by 4.9% and is now trading at $0.98. How do I buy shares of Semper Paratus Acquisition? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Semper Paratus Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that Semper Paratus Acquisition investors own include NVIDIA (NVDA), Candel Therapeutics (CADL), CXApp (CXAI), GlycoMimetics (GLYC), Rigetti Computing (RGTI), XTI Aerospace (XTIA) and Aldeyra Therapeutics (ALDX). Company Calendar Today8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Semper Paratus Acquisition$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+915.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.73 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-934.56% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-10.94Miscellaneous Outstanding Shares183,890,000Free Float49,210,000Market Cap$181.13 million OptionableN/A Beta-0.77 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TVGN) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semper Paratus Acquisition Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Semper Paratus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.